Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 9—September 2020

Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients

Yin Mo1Comments to Author , Anastasia Hernandez-Koutoucheva1, Patrick Musicha, Denis Bertrand, David Lye, Oon Tek Ng, Shannon N. Fenlon, Swaine L. Chen, Moi Lin Ling, Wen Ying Tang, Timothy Barkham, Niranjan Nagarajan, Ben S. Cooper, and Kalisvar Marimuthu
Author affiliations: National University Hospital, Singapore (Y. Mo); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (Y. Mo, A. Hernandez-Koutoucheva, P. Musicha, B.S. Cooper); National University of Singapore, Singapore (Y. Mo, D. Lye, S.L. Chen, N. Nagarajan, K. Marimuthu); Genome Institute of Singapore, Singapore (D. Bertrand, S.N. Fenlon, S.L. Chen, N. Nagarajan); University of Oxford, Oxford, UK (P. Musicha, B.S. Cooper); Nanyang Technological University (D. Lye, O.T. Ng); National Centre for Infectious Diseases, Singapore (D. Lye, O.T. Ng, K. Marimuthu); Tan Tock Seng Hospital, Singapore (D. Lye, W.Y. Tang, T. Barkham, K. Marimuthu); Singapore General Hospital, Singapore (M.L. Ling)

Main Article


Demographics for 21 participants in study of duration of carbapenemase-producing Enterobacteriaceae carriage in hospital patients, Singapore*

No. (%)
M 15 (71.4)
6 (28.6)
Chinese 15 (71.4)
Malay 3 (14.3)
Indian 2 (9.5)
1 (4.8)
Ambulatory status
Independently performs ADL 12 (57.1)
Requires assistance in ADL 4 (19.0)
Wheelchair bound 3 (14.3)
Bed bound
2 (9.5)
Recent surgery†
15 (71.4)
Colonization or infection with another MDRO in the year preceding enrollment 4 (19.0)
Hospitalization in past year 11 (52.4)
Antibiotic intake during follow-up period 13 (61.9)
Readmission during follow-up period 10 (47.6)
Recent overseas travel 13 (61.9)

*Median age (interquartile range) was 60.0 (50.0–69.0) y; median Charlson Morbidity Index (interquartile range) 3.0 (2.0–5.0). ADL, activities of daily living; MDRO, multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumanii, and carbapenem-resistant Pseudomonas aeruginosa, recorded from surveillance and clinical cultures taken in the year before study enrollment.
†Gastrointestinal surgeries (n = 7), skin and soft tissue surgeries (n = 4), neurosurgery (n = 2), removal of Tenckhoff catheter (n = 1), and urologic procedure (n = 1).

Main Article

1These authors contributed equally to this article.

Page created: July 10, 2020
Page updated: August 19, 2020
Page reviewed: August 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.